Role of xenoestrogens and endogenous sources of estrogens on the occurrence of premenopausal breast cancer in Iran

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 9, 2011, Pages 2425-2430

  Bidgoli, Sepideh Arbabi ^a   Eftekhari, Tara ^b   Sadeghipour, Reza ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adiposity; AhR; Breast cancer; Endogenous estrogens; Xenoestrogens

Indexed keywords

AROMATIC HYDROCARBON; AROMATIC HYDROCARBON RECEPTOR; DIOXIN; ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; EPITHELIUM CELL; FEMALE; HUMAN; IRAN; METABOLISM; POLLUTANT; PREMENOPAUSE; RISK FACTOR; SMOKING;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; DIOXINS; ENVIRONMENTAL POLLUTANTS; EPITHELIAL CELLS; ESTROGENS; FEMALE; HUMANS; HYDROCARBONS, AROMATIC; IRAN; PREMENOPAUSE; RECEPTORS, ARYL HYDROCARBON; RISK FACTORS; SMOKING;

EID: 84864067312     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Azari MR, Falak F, Masoudinejad MR (2011). Assessment of dioxin-like compounds released from Iranian industries and municipalities. Tanaffos, 6, 59-64.
2. Balabanic D, Rupnik M, Klemencic AK (2011). Negative impact of endocrine-disrupting compounds on human reproductive health. Reprod Fertil Dev, 23, 403-16.
3. Band PR, Le ND, Fang R, et al. (2002). Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet, 360, 1044-9.
4. Berstad P, Coates RJ, Bernstein L, et al. (2010). A case-control study of body mass index and breast cancer risk in white and African-American women. Cancer Epidemiol Biomarkers Prev, 19, 1532-44.
5. Bidgoli HH, Bogg L, Hasselberg M (2011). Pre-hospital trauma care resources for road traffic injuries in a middle-income country-a province based study on need and access in Iran. Injury, 42, 879-84.
6. Bidgoli SA, Ahmadi R, Zavarhei MD (2010b). Role of hormonal and environmental factors on early incidence of breast cancer in Iran. Sci Total Environ, 408, 4056-61.
7. Bidgoli H, Zamani A, Taherzadeh MJ (2010a). Effect of carboxymethylation conditions on the water-binding capacity of chitosan-based superabsorbents. Carbohydr Res, 345, 2683-9.
8. Bray F, McCarron P, Parkin DM (2004). The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res, 6, 229-39.
9. Brisken C (2008). Endocrine disruptors and breast cancer. Chimia, 62, 406-9.
10. Chen JQ, Brown TR, Russo J (2009). Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta, 1793, 1128-43.
11. Chiam K, Tilley WD, Butler LM, et al. (2009). The dynamic and static modification of the epigenome by hormones: a role in the developmental origin of hormone related cancers. Biochim Biophys Acta, 1795, 104-9.
12. Cogliano V, Grosse Y, Baan R, et al. (2005). Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol, 6, 552-3.
13. Fenichel P, Brucker-Davis F (2008). Environmental endocrine disruptors and breast cancer: new risk factors? Gynecol Obstet Fertil, 36, 969-77.
14. Gammon MD, Santella RM, Neugut AI et al. (2002). Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev, 11, 677-85.
15. Habanova M, Svikruhova J, Slavikova E (2010). Hormonal contraceptives and their relationship to breast cancer. Klin Onkol, 23, 428-32.
16. IARC (2007) Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy.'IARC
17. Kamangar F, Strickland PT, Pourshams A, et al. (2005). High exposure to polycyclic aromatic hydrocarbons may contribute to high risk of esophageal cancer in northeastern Iran. Anticancer Res, 25, 425-8.
18. Kolahdoozan S, Sadjadi A, Radmard AR, et al. (2010). Five common cancers in Iran. Arch Iran Med, 13, 143-6.
19. Lee KH, Shu XO, Gao YT, et al. (2010). Breast cancer and urinary biomarkers of polycyclic aromatic hydrocarbon and oxidative stress in the Shanghai Women's Health Study. Cancer Epidemiol. Biomarkers Prev, 19, 877-83.
20. Liu S, Abdelrahim M, Khan S, et al. (2006). Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol Chem, 387, 1209-13.
21. Onland-Moret NC, Kaaks R, van Noord PA, et al. (2003). Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer, 88, 1394-9.
22. Salehi F, Turner MC, Phillips KP, et al. (2008). Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors. J Toxicol Environ. Health B Crit Rev, 11, 276-300.
23. Soran A, Talbott EO, Zborowski JV, et al. (2005). The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract, 59, 795-7.
24. Sung MK, Yeon JY, Park SY, et al. (2011). Obesity-induced metabolic stresses in breast and colon cancer. Ann NY Acad Sci, 1229, 61-8.
25. Van der HE, Bechoux N, Muller M, et al. (2009). Food flavonoid aryl hydrocarbon receptor-mediated agonistic/antagonistic/synergic activities in human and rat reporter gene assays. Anal Chim Acta, 637, 337-45.
26. Vogel CF, Li W, Wu D, et al. (2011). Interaction of aryl hydrocarbon receptor and NF-kappaB subunit RelB in breast cancer is associated with interleukin-8 overexpression. Arch Biochem Biophys, 512, 78-86.
27. Wu MH, Chou YC, Chou WY, et al. (2009). Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer, 100, 578-82.
28. Zhang JJ, Wang M (2010). Latent class joint model of ovarian function suppression and DFS for premenopausal breast cancer patients. Stat Med, 29, 2310-24.